Cipla will distribute Eli Lilly’s weight-loss and diabetes drug tirzepatide — popular across the world as Mounjaro — in India.

While Cipla will sell it under the brand name Yurpeak — the drug will be available in a pen-like device, in six different strengths, and pegged at the same price as Mounjaro in India. Lilly brought Mounjaro to India in March 2025, and announced its pen-like devices in June.

Multinational Eli Lilly and Cipla announced an agreement to this effect on Thursday, marking Cipla’s entry into the obesity segment — something its top management has been indicating in previous interactions with businessline .

Broader access

Cipla now has the rights to distribute and promote Yurpeak — as the second brand of tirzepatide in India. This would expand the availability of tirze

See Full Page